GI
NBIX icon

GAMMA Investing’s Neurocrine Biosciences NBIX Stock Holding History

GAMMA Investing’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$547K Buy
3,858
+144
+4% +$23.1K 0.02% 659
2026
Q2 		$626K Buy
3,714
+868
+30% +$129K 0.02% 552
2026
Q1 		$375K Sell
2,846
-198
-7% -$26.3K 0.02% 717
2025
Q4 		$432K Buy
3,044
+358
+13% +$51.9K 0.02% 590
2025
Q3 		$377K Buy
2,686
+331
+14% +$44.8K 0.02% 609
2025
Q2 		$296K Buy
2,355
+374
+19% +$42.9K 0.02% 680
2025
Q1 		$219K Sell
1,981
-314
-14% -$39.8K 0.02% 719
2024
Q4 		$313K Buy
2,295
+557
+32% +$68.9K 0.03% 526
2024
Q3 		$200K Buy
1,738
+185
+12% +$25.4K 0.02% 624
2024
Q2 		$214K Buy
1,553
+395
+34% +$54.2K 0.03% 479
2024
Q1 		$160K Buy
1,158
+310
+37% +$42.3K 0.03% 470
2023
Q4 		$119K Buy
+848
New +$97.6K 0.03% 477

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

GAMMA Investing's NBIX Position: Q3 2026 in Review

GAMMA Investing increased its Neurocrine Biosciences (NBIX) stake by 3.9% in Q3 2026, buying an estimated $23.1K and bringing the position to 3,858 shares worth $547K. The position accounts for 0.02% of the portfolio, ranked #659.

GAMMA Investing first reported a position in NBIX in Q4 2023 and has held it in 12 quarters since. The position peaked at $626K in Q2 2026. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • GAMMA Investing held 3,858 shares of Neurocrine Biosciences worth $547K as of Q3 2026.
  • GAMMA Investing bought 144 Neurocrine Biosciences shares in Q3 2026, an estimated $23.1K.
  • Neurocrine Biosciences made up 0.02% of GAMMA Investing's portfolio in Q3 2026, its #659 holding.
  • GAMMA Investing first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Neurocrine Biosciences position peaked at $626K in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.